Clearmind Medicine Inc. (NASDAQ: CMND) reported that 20 participants have been treated in its ongoing Phase I/IIa clinical trial evaluating CMND-100 for moderate to severe alcohol use disorder, according to a company statement.

The Vancouver-based biotech company said two additional participants were dosed in the trial's fourth cohort at Hadassah-University Medical Center in Jerusalem. The fourth cohort involves a higher dose of CMND-100 at 160 mg, following a positive recommendation from the Data and Safety Monitoring Board and completion of the third cohort in April 2026.

The company stated that the first three cohorts, which included 18 participants, met the primary safety endpoint with no serious adverse events reported. The trial is designed to evaluate safety, tolerability, pharmacokinetics, and preliminary efficacy of CMND-100 in patients with moderate to severe alcohol use disorder.

"The consistent safety data observed so far across all cohorts reinforces our confidence in CMND-100 and brings us closer to potentially delivering a much-needed new therapeutic option for patients struggling with alcohol use disorder," said Dr. Adi Zuloff-Shani, Chief Executive Officer of Clearmind Medicine.

The FDA-approved trial is being conducted at multiple institutions including Yale School of Medicine, Johns Hopkins University School of Medicine, Tel Aviv Sourasky Medical Center, and Hadassah Medical Center.

Clearmind describes itself as a clinical-stage company focused on developing non-hallucinogenic, neuroplastogen-derived therapeutics. The company's intellectual portfolio includes 19 patent families with 31 granted patents.